Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Gilbert Lee

Plastic and Reconstructive Surgery San Diego, CA Medical Doctor

NPI 1417037680 CMS profile 64150

11515 El Camino Real, Suite 150, San Diego, CA 92130

Open in the dashboard

General payments

$5,012

100 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Gilbert Lee of San Diego, CA is reported in the CMS Open Payments database as having received $5,012 across 100 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $857 15
2023 General $664 14
2022 General $1,239 21
2021 General $1,023 18
2020 General $265 13
2019 General $963 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gilbert Lee
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Gilbert Lee were reported at $0. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Gilbert Lee Plastic and Reconstructive Surgery median Middle half National median
2019 $963 $335 $121–$1,264 $163
2020 $265 $162 $57–$417 $114
2021 $1,023 $245 $89–$735 $132
2022 $1,239 $325 $120–$932 $149
2023 $664 $343 $129–$999 $160
2024 $857 $390 $141–$1,085 $164
2025 $0 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Sientra, Inc. $1,240 7 payments
  2. TELA Bio, Inc. $1,000 12 payments
  3. Galderma Laboratories, L.P. $713 32 payments
  4. Allergan Inc. $381 17 payments
  5. Integra LifeSciences Corporation $377 3 payments
  6. AbbVie, Inc. $265 9 payments
  7. AcelRx Pharmaceuticals, Inc. $167 3 payments
  8. Kerecis Limited $165 1 payment
  9. PolyNovo North America LLC $153 1 payment
  10. W. L. Gore & Associates, Inc. $125 1 payment
  11. Other $426 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $4,686 99 payments
  2. Long term medical supply or device loan $326 1 payment
Products named General payments · program years 2019–2024
  1. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $1,240 7 payments
  2. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $828 11 payments
  3. DuraSorb Monofilament Mesh $326 1 payment
  4. OviTex 2S $172 1 payment
  5. DSUVIA $167 3 payments
  6. Kerecis Omega3 SurgiClose Wound Care $165 1 payment
  7. Kerecis Omega3 SurgiClose Wound Care $165 1 payment
  8. Kerecis Omega3 SurgiClose Wound Care $165 1 payment
  9. Kerecis Omega3 GraftGuide $165 1 payment
  10. Kerecis Omega3 Marigen $165 1 payment
  11. Other $1,272 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

48

Median for General Surgery: 59

Drug cost

$326

Median for General Surgery: $393

Branded share of claims

52.1%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 11 $159
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 14 $84
Losartan Potassium Generic 11 $51
Cephalexin Generic 12 $32

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DYSPORT
  • Galderma Laboratories, L.P. $71
$71 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $30
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

100 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic and Reconstructive Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record